Predicting Outcomes After Hematopoietic Stem Cell Transplant for Myelodysplastic Syndromes
A personalized prediction model for probability of survival in patients with MDS who undergo HCT is presented at the ASH 2018 Annual Meeting.
ASH 2018
Yescarta in the Real-World Setting: How Did the Results Compare With ZUMA-1 Outcomes?
Inferior patient outcomes from treatment with axi-cel were linked to poor performance status and increased tumor bulk in patients.
No Survival Benefit Found With Allogeneic Hematopoietic Cell Transplantation in Older Patients With AML
At first glance, the data on 695 patients with advanced myeloid leukemia (AML) seem to support a survival advantage of allogeneic hematopoietic cell transplantation (HCT) compared with no transplantation.
A Retrospective Look at Drug Sensitivity Before and After Checkpoint Blockade in R/R NHL
Checkpoint-based therapies may sensitize patients to subsequent therapies.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASH 2018
Loading... 
Loading...